| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 (NCT03185494) | Chinese PLA General Hospital | 2017-08-01 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770) | Chinese PLA General Hospital | 2017-04-01 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (NCT02797470) | AIDS Malignancy Consortium | 2016-06-23 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (NCT02685670) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2016-02-01 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (NCT02652910) | Xinqiao Hospital of Chongqing | 2015-12-01 |
| Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma (NCT02242097) | Northwestern University | 2015-01-12 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (NCT02213913) | University of Chicago | 2014-07-29 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (NCT01959477) | Case Comprehensive Cancer Center | 2014-03-01 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037) | Northwestern University | 2013-03-05 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy (NCT01735604) | Chinese PLA General Hospital | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation (NCT01267812) | City of Hope Medical Center | 2011-10-03 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy (NCT01029366) | University of Pennsylvania | 2010-03-17 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT01045928) | Case Comprehensive Cancer Center | 2010-01-01 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (NCT01044745) | University of Nebraska | 2009-12-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00769288) | National Cancer Institute (NCI) | 2009-07-01 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT00891072) | National Cancer Institute (NCI) | 2009-07-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT00601718) | University of Washington | 2007-12-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (NCT00499811) | National Cancer Institute (NCI) | 2007-06-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (NCT00458731) | National Cancer Institute (NCI) | 2007-05-01 |
| Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma (NCT00433537) | National Cancer Institute (NCI) | 2007-05-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00293345) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (NCT00354185) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (NCT00275080) | National Cancer Institute (NCI) | 2006-02-01 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (NCT00101244) | National Cancer Institute (NCI) | 2004-11-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function (NCT00118170) | National Cancer Institute (NCI) | 2004-10-01 |
| 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas (NCT00089271) | National Cancer Institute (NCI) | 2004-07-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma (NCT00060112) | National Cancer Institute (NCI) | 2003-03-01 |
| Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction (NCT00054483) | National Cancer Institute (NCI) | 2003-01-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma (NCT00017381) | National Cancer Institute (NCI) | 2001-04-01 |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer (NCT00010192) | National Cancer Institute (NCI) | 2000-12-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |
| Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NCT00019708) | National Cancer Institute (NCI) | 1999-06-01 |
| Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma (NCT00003970) | National Cancer Institute (NCI) | 1999-01-01 |
| Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma (NCT00003502) | Burzynski Research Institute | |